Current Oncology Reports最新文献_第4页

Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors. 多学科治疗局部胃食管交界处肿瘤的当前标准和争议。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-07 DOI: 10.1007/s11912-024-01606-6

Emily T Santos, Deenah Baig, Nina N Sanford

{"title":"Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors.","authors":"Emily T Santos, Deenah Baig, Nina N Sanford","doi":"10.1007/s11912-024-01606-6","DOIUrl":"10.1007/s11912-024-01606-6","url":null,"abstract":"Purpose of review: There has been controversy in the management of gastroesophageal (GE) junction cancers with pre-operative chemoradiation and peri-operative chemotherapy as accepted practices. We aim to assess and compare the defining trials establishing current standards of care and discuss future directions seeking to further improve patient-centered outcomes in GE junction cancers.Recent findings: Over the last two decades, several large Phase III randomized trials have been conducted including GE junction cancers, showing superiority of 1) pre-operative chemoradiation over surgery (CROSS) and 2) peri-operative chemotherapy with FLOT over CROSS without radiotherapy (FLOT 4). While NEO-Aegis suggested equipoise between the CROSS vs. peri-operative chemotherapy, the recently presented ESOPEC trial demonstrated superiority of peri-operative FLOT versus CROSS in esophagus and GE junction adenocarcinomas. Based on the ESOPEC trial, peri-operative chemotherapy with FLOT appears to be a preferred regimen for patients with resectable GE junction adenocarcinomas in patients able to receive FLOT. There is evidence in support of other practices, such as induction chemotherapy, pre-operative chemoradiation, definitive chemoradiation for those not fitting ESOPEC criteria. Chemoradiation ± chemotherapy with non-operative intent represents a promising strategy for patients seeking organ preservation, and ongoing studies will better define its feasibility and long-term outcomes.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1606-1611"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review. 治疗常见癌症脑转移的免疫治疗和靶向策略：最新研究综述》。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-08 DOI: 10.1007/s11912-024-01593-8

Vivek Podder, Shreyas Bellur, Kim Margolin, Pooja Advani, Reshma L Mahtani, Vivek Subbiah, Gabriella B Novo, Tulika Ranjan, Manmeet S Ahluwalia

{"title":"Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review.","authors":"Vivek Podder, Shreyas Bellur, Kim Margolin, Pooja Advani, Reshma L Mahtani, Vivek Subbiah, Gabriella B Novo, Tulika Ranjan, Manmeet S Ahluwalia","doi":"10.1007/s11912-024-01593-8","DOIUrl":"10.1007/s11912-024-01593-8","url":null,"abstract":"Purpose of review: This review examines contemporary strategies for managing brain metastases (BM) from common cancers such as lung, breast, and melanoma. We evaluate the efficacy and applicability of targeted therapies and immunotherapies, exploring their potential to cross the blood-brain barrier and improve patient outcomes.Recent findings: Recent studies have shown that tyrosine kinase inhibitors, immune checkpoint inhibitors, and ADCs effectively treat BM. These treatments can overcome the challenges posed by the blood-brain barrier and improve therapeutic outcomes. ADCs are promising because they can deliver cytotoxic agents directly to tumor cells, which reduces systemic toxicity and increases drug delivery efficiency to the brain. Personalized medicine is becoming increasingly significant in treatment decisions, with biomarkers playing an essential role. Advances in molecular genetics and drug development have led to more refined treatments, emphasizing the precision medicine framework. The management of BM is evolving, driven by drug efficacy, resistance mechanisms, and the need for personalized medicine. Integrating ADCs into treatment regimens represents a significant advancement in targeting metastatic brain tumors. Despite these advances, BM management still presents considerable challenges, requiring ongoing research and multi-institutional trials to optimize therapeutic strategies. This review outlines the current state and future directions in treating BM, highlighting the critical need for continued innovation and comprehensive clinical evaluations to improve survival rates and quality of life for affected patients.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1612-1638"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telemedicine and Virtual Interventions in Cancer Rehabilitation: Practical Application, Complications and Future Potentials. 癌症康复中的远程医疗和虚拟干预：癌症康复中的远程医疗和虚拟干预：实际应用、并发症和未来潜力》。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1007/s11912-024-01612-8

Philip Chang, Jessica Engle

引用次数: 0

Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review. 平衡青少年和年轻成人乳腺癌患者（新）辅助治疗中的生育力保护和治疗效果：叙述性综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-05 DOI: 10.1007/s11912-024-01615-5

Yuji Tanaka, Tsukuru Amano, Akiko Nakamura, Akimasa Takahashi, Akie Takebayashi, Tetsuro Hanada, Shunichiro Tsuji, Takashi Murakami

{"title":"Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review.","authors":"Yuji Tanaka, Tsukuru Amano, Akiko Nakamura, Akimasa Takahashi, Akie Takebayashi, Tetsuro Hanada, Shunichiro Tsuji, Takashi Murakami","doi":"10.1007/s11912-024-01615-5","DOIUrl":"10.1007/s11912-024-01615-5","url":null,"abstract":"Purpose of review: Adolescent and young adult (AYA) breast cancer survivors face a significant risk of infertility due to the gonadotoxic effects of (neo)adjuvant therapy, which complicates their ability to conceive post-treatment. While (neo)adjuvant therapy primarily aims to improve recurrence-free and overall survival, fertility preservation strategies should also be considered for young patients. This narrative review explores recent advancements in fertility preservation techniques, such as oocyte, embryo, and ovarian tissue cryopreservation, and evaluates the feasibility of modifying breast cancer (neo)adjuvant therapy to preserve fertility without compromising survival outcomes.Recent findings: Our review highlights that clinical trials with co-primary endpoints of oncological safety and fertility preservation are limited, and substituting standard treatment regimens solely for fertility preservation is currently not recommended. Nevertheless, new clinical studies have emerged that either exclude highly ovarian-toxic agents, such as cyclophosphamide, or omit adjuvant therapy altogether, even if fertility preservation is not their primary endpoint. Unfortunately, many of these trials have not evaluated ovarian toxicity. Notably, since 2020, major oncology organizations, including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) have advocated for the routine assessment of ovarian toxicity in all clinical trials. The review underscores the importance of incorporating ovarian toxicity as a standard endpoint in future trials involving premenopausal breast cancer patients to identify treatment regimens that can effectively balance fertility preservation with treatment efficacy.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1563-1574"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast cancer Treatment and Fertility Preservation: A Narrative Review of Impacts, Strategies and Ethical Considerations. 乳腺癌治疗与生育力保护：影响、策略和伦理考虑的叙述性回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1007/s11912-024-01619-1

Prakriti Anuj Sachdev, Natalie George Ayad, Constantina Constantinou

{"title":"Breast cancer Treatment and Fertility Preservation: A Narrative Review of Impacts, Strategies and Ethical Considerations.","authors":"Prakriti Anuj Sachdev, Natalie George Ayad, Constantina Constantinou","doi":"10.1007/s11912-024-01619-1","DOIUrl":"10.1007/s11912-024-01619-1","url":null,"abstract":"Purpose of review: At present, breast cancer represents the most common malignancy diagnosed in women worldwide. Due to the trend toward delayed childbearing, many women of reproductive age are being diagnosed with breast cancer and treated with chemotherapy or hormone therapy which can adversely affect their fertility. This literature review discusses the effects of breast cancer treatment on fertility and options for fertility preservation.Recent findings: Treatments used in the management of breast cancer often result in a diminished ovarian reserve, premature ovarian insufficiency, and treatment-related amenorrhea. Chemotherapy may cause direct damage to oocytes and deplete ovarian reserve, while hormone therapies such as tamoxifen can cause amenorrhea and delay childbearing. Targeted therapies and radiotherapy may also pose risks to reproductive health. Fertility preservation is a concern for patients, and many of them may refuse or prematurely discontinue treatment to preserve their fertility. It is relevant to incorporate considerations of fertility at the time of treatment planning for breast cancers and to provide information to appropriate patients regarding their options. Current techniques available for fertility preservation include ovarian suppression, oocyte and embryo cryopreservation, and ovarian tissue cryopreservation. In spite of these techniques being in existence, there are plenty of barriers that deter the patients from availing them, including lack of awareness, financial constraints, and the need for timely treatment. This review implicates that these challenges require multidisciplinary approaches and a patient-centered approach. Further research is warranted toward the improvement of fertility preservation techniques, individual variability in protocols, and newer advances in reproductive medicine to further optimize quality of life in survivors of breast cancer.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1575-1585"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. Talimogene laherparepvec (T-VEC) 和治疗转移性黑色素瘤的新兴瘤内免疫疗法：综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1007/s11912-024-01611-9

Simran Kalsi, Amanda L Galenkamp, Rohit Singh, Atulya Aman Khosla, Peter McGranaghan, Jessica Cintolo-Gonzalez

引用次数: 0

Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable. 套细胞淋巴瘤中可测量的残留疾病：无法检测的不可承受之轻。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-12-06 DOI: 10.1007/s11912-024-01620-8

Julio Cartagena, Anagha Deshpande, Allison Rosenthal, Mazie Tsang, Talal Hilal, Lisa Rimsza, Razelle Kurzrock, Javier Munoz

{"title":"Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable.","authors":"Julio Cartagena, Anagha Deshpande, Allison Rosenthal, Mazie Tsang, Talal Hilal, Lisa Rimsza, Razelle Kurzrock, Javier Munoz","doi":"10.1007/s11912-024-01620-8","DOIUrl":"10.1007/s11912-024-01620-8","url":null,"abstract":"Purpose of review: This paper evaluates the benefits and limitations of detecting measurable residual disease (MRD) in mantle cell lymphoma (MCL) and assesses its prognostic value. It also aims to highlight the importance of detecting low MRD levels post-treatment and their application in clinical practice.Recent findings: Recent studies show that MRD levels predict relapse and survival outcomes in hematologic neoplasms, including MCL. RT-qPCR is currently the most used method due to its high reproducibility and sensitivity. Ideal MRD detection should be highly sensitive, cost-effective, and applicable to a wide demographic of patients. This paper concludes that MRD detection has prognostic value in MCL but faces limitations in sensitivity and specificity. Further research is needed to establish the significance of low MRD levels before integrating these methods into clinical practice. Improved MRD detection technologies and understanding their impact on clinical outcomes will guide better patient management in MCL.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1664-1674"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Existing Health Inequities in the Treatment of Advanced and Metastatic Cancers. 晚期和转移性癌症治疗中现有的健康不平等。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-04 DOI: 10.1007/s11912-024-01617-3

Navya Nair, Matthew Schlumbrecht

{"title":"Existing Health Inequities in the Treatment of Advanced and Metastatic Cancers.","authors":"Navya Nair, Matthew Schlumbrecht","doi":"10.1007/s11912-024-01617-3","DOIUrl":"10.1007/s11912-024-01617-3","url":null,"abstract":"Purpose of review: This study aims to identify health inequities related to the medical treatment and supportive care of patients with advanced/metastatic cancer and recommend solutions to promote health equity.Recent findings: Despite robust strides in the development of therapeutic strategies for advanced and metastatic cancer, significant disparities in treatment access and implementation exist. Race, socioeconomic status, gender, and geography represent just a few of the individual-level factors which contribute to challenges in treatment administration, thorough evaluation of germline genetics and tumor genomics, and quality palliative and end-of-life care. Given the increasing complexity of cancer treatments and our enhanced understanding of tumor biology, efforts to uniformly provide equitable and high-level care to all patients are needed. In this review we will discuss factors that contribute to health inequities in patients with advanced and metastatic cancer diagnoses, highlighting opportunities for intervention, ongoing challenges in change implementation, and national and international society recommendations to eliminate disparities. Acknowledging existing inequities and engaging in multilevel discourse with key stakeholders is needed to optimize care practices to the benefit of all patients.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1553-1562"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis. 为预后良好的转移性肾细胞癌患者提供Tivozanib单药前线治疗

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-20 DOI: 10.1007/s11912-024-01613-7

Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J Goebell

{"title":"Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.","authors":"Ricky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, Omi Parikh, Laura-Maria Krabbe, Naveen S Vasudev, Christian Doehn, Norbert Marschner, Tom Waddell, Will Ince, Peter J Goebell","doi":"10.1007/s11912-024-01613-7","DOIUrl":"10.1007/s11912-024-01613-7","url":null,"abstract":"Purpose of review: In this review, we discuss which patients with metastatic clear cell renal cell carcinoma (mRCC) may be most suitable for frontline tyrosine kinase inhibitor (TKI) monotherapy, a treatment option supported by emerging long-term efficacy data including overall survival and quality of life. We specifically focus on tivozanib, a potent and selective inhibitor of vascular endothelial growth factor receptor, which has comparable efficacy to other single-agent TKIs in frontline treatment for mRCC while exhibiting fewer off-target side effects.Recent findings: Combination therapy with TKIs and checkpoint inhibitors (CPIs) and CPI/CPI combination therapies, as well as TKI monotherapy are recommended frontline treatment options for mRCC. Treatment decisions are complex and based on several factors, including the patient's International Metastatic RCC Database Consortium risk status, age, comorbidities, and personal preferences related to response, tolerability, and quality of life. TKIs not only serve as backbone of most combination therapies for mRCC, but also remain a viable monotherapy option in the first-line setting for patients in favorable risk groups and those with contraindications to CPI combination therapies. Given that overall survival benefits have not yet been confirmed for CPI-containing combination regimens in favorable risk patients, we argue that frontline single-agent TKI treatment remains a standard of care option for these patients. This is supported by treatment guidelines, even in the era of TKI/CPI combination therapies.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1639-1650"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paediatric Acute Lymphoblastic Leukaemia: A Narrative Review of Current Knowledge and Advancements. 儿童急性淋巴细胞白血病：对当前知识和进展的叙述性回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1007/s11912-024-01608-4

Sarah Elgazar, Constantina Constantinou

{"title":"Paediatric Acute Lymphoblastic Leukaemia: A Narrative Review of Current Knowledge and Advancements.","authors":"Sarah Elgazar, Constantina Constantinou","doi":"10.1007/s11912-024-01608-4","DOIUrl":"10.1007/s11912-024-01608-4","url":null,"abstract":"Purpose of review: This review aims to provide an update on current knowledge regarding paediatric acute lymphoblastic leukaemia (ALL), focusing on recent advancements in diagnosis and treatment, as well as future directions in the field.Recent findings: ALL is the most frequently diagnosed paediatric malignancy, with advances leading to a 90% survival rate. The heterogeneity of childhood ALL requires a precise diagnostic algorithm incorporating morphological, immunophenotypic, and cytogenetic analyses. Research is exploring next-generation sequencing and artificial intelligence-aided techniques for future diagnostic approaches. Despite these advancements, global disparities in healthcare access hinder prompt diagnosis and management. The pathophysiology of ALL involves chromosomal and genetic alterations which disrupt cell-cycle regulation and result in uncontrolled lymphoblast proliferation. Environmental factors also contribute to leukaemogenesis. Risk-stratification based on genetic subtypes has significant implications for risk-based therapy. Chemotherapy is administered in three phases: induction, consolidation, and maintenance, with prophylactic intrathecal chemotherapy considered essential. For high-risk, refractory, or relapsed ALL, haematopoietic stem cell transplantation and novel therapies such as tyrosine kinase inhibitors, chimeric antigen receptor T-cell therapy, and blinatumomab immunotherapy, have improved outcomes. Ongoing clinical trials aim to further improve treatment efficacy, reduce toxicity, and increase survival. Although prevention strategies for ALL exist at three levels, the supporting evidence remains limited, highlighting a need for further research. Continued research and clinical trials are essential to addressing the gaps treatment efficacy and prevention strategies. Efforts to improve global healthcare access and integrate novel diagnostic and therapeutic approaches are crucial for advancing outcomes for paediatric patients with ALL.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1586-1599"},"PeriodicalIF":4.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0